Unbiased AI-powered news
1 stories related to this topic, newest first.
New York PostA Cleveland Clinic analysis of 12,112 patients found lower rates of progression to stage 4 disease among those taking GLP-1 medications compared with DPP-4 inhibitors. The observational results will be presented at the 2026 ASCO Annual Meeting.